<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=357056486742139&amp;ev=PageView&amp;noscript=1">
Skip to content
    inicio- (1)
    ather-banner-desktop
    athero-banner-version-mobile

    Cardiovascular disease (CVD) is the leading cause of global mortality, resulting in approximately 18 million deaths each year2, according to the WHO1. In Colombia, CVD accounted for 29% of total mortality in 2021, causing 94,432 deaths and a 16.5% health spending. This has also led to a 0.3% loss in GDP3,4. To combat this issue, ATHERO was established as a public-private alliance committed to controlling risk factors, preventing CVD, and optimizing patient access to treatment.

    ATHERO is an alliance that brings together nine entities from the public and private sectors, with a focus on improving cardiovascular health through three main pillars:

    Health in the territories
    Health in the territories: Our objective is to continue revolutionizing care in primary and secondary prevention. In 2023, we managed to impact territories such as Quindío and Bolívar, specifically Cartagena de Indias, by mapping Colombian experiences in cardiovascular health.
    Technological and social innovation:

    Technological and social innovation: Generate impact through technology in knowledge update processes like ATHERO LAB and through open innovation challenges to have a positive influence in CVD.

    Raising Awareness of Cardiovascular Diseases in Colombia

    Raising Awareness of Cardiovascular Diseases in Colombia: Our mission is to raise awareness about the importance of cardiovascular health and save lives through innovative solutions. In 2023, we launched our  "Manos que Salvan Vidas" campaign, which aims to prevent the sudden death of 1 in 5 people at risk.

    We are confident that, with ATHERO, we are shaping a future where cardiovascular care in Colombia reaches world-class standards, saving lives and enhancing the nation's health. Together, we are making a difference!

    We invite you to learn more about our partners and their profiles. Join us in this fight for life!

    Ministerio de Comercio
    Potencia de la vida
    Innpulsa
    CEmprende
    Sociedad Colombiana de Cardiologia
    Acmi
    Voces diabetes
    camaracomercio
    laboratirosynlab
    Universidad el Bosque
    Connect
    Novartis
    athero

    Taking actions for cardiovascular health in Colombia

    References

    1.  National Administrative Department of Statistics - DANE (2023). Vital Statistics System (EEVVV). Consulted on October 13, 2023 through the Vital Statistics cube of Sispro (Ministry of Health).
    2. Ministry of Health and Social Protection - MinSalud. UPC Sufficiency Cube. 2023. Consultation for the period 2021. Available at: https://www.SISPRO.gov.co/Pages/Home .aspx [Accessed in October 2023].
    3. Portfolio. 1.7 billion a year is invested in preventive health care. 2023. Available at: https://www.portafolio.co/economia/gobierno/salud-recibe-inversion-anual-de-1-7-billones-de-pesos-581848  [Accessed October 2023].
    4. Stevens B, Pezzullo L, Verdian L, et al. The Economic Burden of Heart Disease in Latin America. Poster presented at the World Congress of Cardiology and Cardiovascular Health, 2016, and on the ConsultorSalud portal: https://consultorsalud.com/colombia-invierte-64-billones-al-ano-en-tratar-enfermedades-cardiacas  [Accessed October 2023].

    This material is non-promotional in language, appearance, and intent. Any reference to products or indications not approved by the regulatory authority of the country is strictly for educational purposes, genuine scientific exchange, and to present treatment alternatives in a balanced, comprehensive, and current manner. This material is intended for the general public and is not meant to substitute or replace a clinical or therapeutic decision. For more information, please contact the Medical Department of Novartis S.A. Colombia at 6544444 or via email at informacion.cientifica@novartis.com. To report an adverse event, please visit the following link: https://www.report.novartis.com/es or contact us via email at colombia.farmacovigilancia@novartis.com. Recording, photography, distribution, and unauthorized dissemination of this material are not permitted by Novartis. Colombia. Novartis de Colombia S.A., Calle 93B No. 16-31. PBX 654 44 44. Bogotá, D.C. Novartis de Colombia S.A. Novartis Pharma AG, Basel, Switzerland. ® = Trademark. Approval Date: 15/12/2023 Valid until: 20/11/2025 P3 Number: CO2312154657.
    novartis